



List of infectious diseases

This is a list of infectious diseases arranged by name, along with the infectious agents that cause them, the vaccines that can prevent or cure them when they exist and their current status. Some on the list are vaccine-preventable diseases.

List

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Acinetobacter baumannii</u>	<u>Acinetobacter</u> infections	Culture	Supportive care	No
<u>Actinomyces israelii</u> , <u>Actinomyces gerencseriae</u> and <u>Propionibacterium propionicus</u>	<u>Actinomycosis</u>	Histologic findings	Penicillin, <u>doxycycline</u> , and <u>sulfonamides</u>	No
<u>Adenoviridae</u>	<u>Adenovirus infection</u>	Antigen detection, polymerase chain reaction assay, virus isolation, and serology	Most infections are mild and require no therapy or only symptomatic treatment.	<u>Under research</u> ^[1]
<u>Trypanosoma brucei</u>	African sleeping sickness (African trypanosomiasis)	Identification of trypanosomes in a sample by microscopic examination	<u>Fexinidazole</u> by mouth or pentamidine by injection for <i>T. b. gambiense</i> . <u>Suramin</u> by injection is used for <i>T. b. rhodesiense</i>	<u>Under research</u> ^[2]
HIV (Human immunodeficiency virus)	<u>AIDS (acquired immunodeficiency syndrome)</u>	Antibody test, p24 antigen test, PCR	Treatment is typically a <u>non-nucleoside reverse transcriptase inhibitor (NNRTI)</u> plus two nucleoside analog reverse transcriptase inhibitors (NRTIs)	<u>Under research</u> ^[3]
<u>Entamoeba histolytica</u>	<u>Amoebiasis</u>	Microscopy	Those with symptoms require treatment with an amoebicidal tissue-active agent and a luminal cysticidal agent. Individuals that are asymptomatic only need a luminal cysticidal agent.	No
<u>Anaplasma</u> species	<u>Anaplasmosis</u>	indirect immunofluorescence antibody assay for IgG	Tetracycline drugs (including <u>tetracycline</u> , <u>chlortetracycline</u> , <u>oxytetracycline</u> , <u>rolitetracycline</u> , <u>doxycycline</u> , and <u>minocycline</u>) and <u>imidocarb</u>	No
<u>Angiostrongylus</u>	<u>Angiostrongyliasis</u>	Lumbar puncture, brain imaging, serology	Albendazole	No
<u>Anisakis</u>	<u>Anisakiasis</u>	Gastroscopic examination, or histopathologic examination	<u>Albendazole</u>	No
<u>Bacillus anthracis</u>	<u>Anthrax</u>	Culture, PCR	Large doses of intravenous and oral antibiotics, such as <u>fluoroquinolones (ciprofloxacin)</u> , <u>doxycycline</u> , <u>erythromycin</u> , <u>vancomycin</u> , or <u>penicillin</u>	<u>Yes</u>
<u>Arcanobacterium haemolyticum</u>	<u>Arcanobacterium haemolyticum</u> infection	Culture in human blood agar plates	<u>erythromycin</u> (proposed as the first-line drug), <u>clindamycin</u> , <u>gentamicin</u> , and <u>cephalosporins</u>	No
<u>Junin virus</u>	<u>Argentine hemorrhagic fever</u>			<u>Yes</u> ^[4]
<u>Ascaris lumbricoides</u>	<u>Ascariasis</u>	<u>Fecal smear</u>	<u>Albendazole</u> , <u>mebendazole</u> , <u>levamisole</u> and <u>pyrantel pamoate</u>	No
<u>Aspergillus</u> species	<u>Aspergillosis</u>	<u>Chest X-ray and CT, microscopy by silver stains</u>	<u>Voriconazole</u> and <u>liposomal amphotericin B</u> in combination with surgical <u>debridement</u>	No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Astroviridae</u> species	<u>Astrovirus</u> infection	Electron microscopy, enzyme-immunoassay (ELISA), immunofluorescence, and polymerase chain reaction	Supportive care	No
<u>Babesia</u> species	<u>Babesiosis</u>	Giemsa-stained thin-film blood smear	<u>Atovaquone</u> and <u>azithromycin</u> . In life-threatening cases, <u>exchange transfusion</u> is performed.	No
<u>Bacillus cereus</u>	<u>Bacillus cereus</u> infection	Culture	<u>Vancomycin</u>	No
multiple bacteria	<u>Bacterial meningitis</u>	Lumbar puncture (contraindicated if there is a mass in the brain or the intracranial pressure is elevated), CT or MRI	Antibiotics	No
multiple bacteria	<u>Bacterial pneumonia</u>	Sputum Gram stain and culture, Chest radiography	Antibiotics	No
List of bacterial vaginosis microbiota	<u>Bacterial vaginosis</u>	Gram stain and whiff test	<u>Metronidazole</u> or <u>clindamycin</u>	No
<u>Bacteroides</u> species	<u>Bacteroides</u> infection			No
<u>Balantidium coli</u>	<u>Balantidiasis</u>	microscopic examination of stools, or colonoscopy or sigmoidoscopy	<u>Tetracycline</u> , <u>metronidazole</u> or <u>iodoquinol</u>	No
<u>Bartonella</u>	<u>Bartonellosis</u>	microscopy, serology, and PCR	Antibiotics	No
<u>Baylisascaris</u> species	<u>Baylisascaris</u> infection			No
BK virus	<u>BK virus</u> infection			No
<u>Piedraia hortae</u>	<u>Black piedra</u>	Stain or culture	Antifungal shampoos such as <u>pyrithione zinc</u> , <u>formaldehyde</u> and <u>salicylic acid</u>	No
<u>Blastocystis</u> species	<u>Blastocystosis</u>	microscopic examination of a chemically preserved stool specimen	Lack of scientific study to support the efficacy of any particular treatment	No
<u>Blastomyces dermatitidis</u>	<u>Blastomycosis</u>	KOH prep, cytology, or histology	<u>Itraconazole</u> or <u>ketoconazole</u>	No
<u>Machupo virus</u>	<u>Bolivian hemorrhagic fever</u>			No
<u>Clostridium botulinum</u> ; Note: Botulism is not an infection by <u>Clostridium botulinum</u> but caused by the intake of <u>botulinum toxin</u> .	Botulism (and Infant botulism)	<u>Enzyme-linked immunosorbent assays</u> (ELISAs), <u>electrochemiluminescent</u> (ECL) tests	Botulism antitoxin and supportive care	No
<u>Sabiá virus</u>	<u>Brazilian hemorrhagic fever</u>			No
<u>Brucella</u> species	<u>Brucellosis</u>	Culture	<u>Tetracyclines</u> , <u>rifampicin</u> , and the <u>aminoglycosides</u> <u>streptomycin</u> and <u>gentamicin</u>	Yes ^[5]
<u>Yersinia pestis</u>	<u>Bubonic plague</u>	Culture	<u>Aminoglycosides</u> such as <u>streptomycin</u> and <u>gentamicin</u> , <u>tetracyclines</u> (especially <u>doxycycline</u>), and the <u>fluoroquinolone</u> <u>ciprofloxacin</u>	Under research ^[6]
usually <u>Burkholderia cepacia</u> and other <u>Burkholderia</u> species	<u>Burkholderia</u> infection			No
<u>Mycobacterium ulcerans</u>	<u>Buruli ulcer</u>	<u>real-time PCR</u>	The most widely used antibiotic regimen is once daily oral <u>rifampicin</u> plus twice daily oral <u>clarithromycin</u> .	No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Caliciviridae</u> species	Calicivirus infection (Norovirus and Sapovirus)			No
<u>Campylobacter</u> species	<u>Campylobacteriosis</u>	Stool culture	<u>Erythromycin</u> can be used in children, and <u>tetracycline</u> in adults.	No
usually <u>Candida albicans</u> and other <u>Candida</u> species	<u>Candidiasis</u> (Moniliasis; Thrush)	oral candidiasis, the person's mouth for white patches and irritation. vaginal candidiasis, vaginal itching or soreness, pain during sexual intercourse	<u>Antifungal medications</u>	No
Intestinal disease by <u>Capillaria philippinensis</u> , hepatic disease by <u>Capillaria hepatica</u> and pulmonary disease by <u>Capillaria aerophila</u>	<u>Capillariasis</u>			No
<u>Streptococcus mutans</u>	<u>Dental caries</u>			<u>Under research</u> ^[7]
<u>Bartonella bacilliformis</u>	<u>Carrion's disease</u>	Peripheral blood smear with Giemsa stain, Columbia blood agar cultures, <u>immunoblot</u> , indirect <u>immunofluorescence</u> , and <u>PCR</u>	Fluoroquinolones (such as <u>ciprofloxacin</u>) or <u>chloramphenicol</u> in adults and <u>chloramphenicol plus beta-lactams</u> in children	No
<u>Bartonella henselae</u>	<u>Cat-scratch disease</u>	<u>Polymerase chain reaction</u>	<u>Azithromycin</u>	No
usually Group A <u>Streptococcus</u> and <u>Staphylococcus</u>	<u>Cellulitis</u>	history and physical examination	Penicillinase-resistant semisynthetic penicillin or a first-generation <u>cephalosporin</u>	No
<u>Trypanosoma cruzi</u>	<u>Chagas disease</u> (American trypanosomiasis)	Microscopic examination of fresh anticoagulated blood, or its buffy coat, for motile parasites; or by preparation of thin and thick <u>blood smears</u> stained with <u>Giemsa</u> .	<u>Benznidazole</u> and <u>nifurtimox</u> (though benznidazole is the only drug available in most of Latin America)	<u>Under research</u> ^[8]
<u>Haemophilus ducreyi</u>	<u>Chancroid</u>	Clinical diagnosis	The <u>CDC</u> recommendation is either a single oral dose (1 gram) of <u>azithromycin</u> , a single IM dose (250 mg) of <u>ceftriaxone</u> , oral (500 mg) of <u>erythromycin</u> three times a day for seven days, or oral (500 mg) of <u>ciprofloxacin</u> twice a day for three days.	No
<u>Varicella zoster virus</u> (VZV)	<u>Chickenpox</u>	The diagnosis of chickenpox is primarily based on the signs and symptoms, with typical early symptoms followed by a characteristic <u>rash</u> .	<u>Aciclovir</u>	<u>Yes</u>
<u>Alphavirus</u>	<u>Chikungunya</u>	Laboratory criteria include a decreased <u>lymphocyte count</u> consistent with <u>viremia</u> . Definitive laboratory diagnosis can be accomplished through	<u>Supportive care</u>	<u>Under research</u> ^[9]

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
		viral isolation, RT-PCR, or <u>serological</u> diagnosis.		
<u>Chlamydia trachomatis</u>	<u>Chlamydia</u>	Nucleic acid amplification tests (NAAT), such as <u>polymerase chain reaction</u> (PCR), <u>transcription mediated amplification</u> (TMA), and the <u>DNA strand displacement amplification</u> (SDA)	<u>azithromycin</u> , <u>doxycycline</u> , <u>erythromycin</u> , <u>levofloxacin</u> or <u>ofloxacin</u>	No
<u>Chlamydophila pneumoniae</u>	<u>Chlamydophila pneumoniae</u> infection (Taiwan acute respiratory agent or TWAR)			No
<u>Vibrio cholerae</u>	<u>Cholera</u>	A rapid <u>dipstick</u> test is available.	<u>oral rehydration therapy</u> (ORT)	<u>Yes</u>
usually <u>Fonsecaea pedrosoi</u>	<u>Chromoblastomycosis</u>	microscopy (KOH scrapings)	<u>Itraconazole</u> , an antifungal <u>azole</u> , is given orally, with or without <u>flucytosine</u> .	No
<u>Batrachochytrium dendrobatidis</u>	<u>Chytridiomycosis</u>			No
<u>Clonorchis sinensis</u>	<u>Clonorchiasis</u>			No
<u>Clostridioides difficile</u>	<u>Clostridioides difficile colitis</u>	<u>Colonoscopy</u> or <u>sigmoidoscopy</u> , cytotoxicity assay, toxin ELISA	<u>Vancomycin</u> or <u>fidaxomicin</u> by mouth	No
<u>Coccidioides immitis</u> and <u>Coccidioides posadasii</u>	<u>Coccidioidomycosis</u>			No
<u>Colorado tick fever virus</u> (CTFV)	<u>Colorado tick fever</u> (CTF)			No
usually <u>rhinoviruses</u> and <u>coronaviruses</u>	<u>Common cold</u> (Acute <u>viral rhinopharyngitis</u> ; Acute coryza)	Based on symptoms	Supportive care	No
<u>Severe acute respiratory syndrome coronavirus 2</u> (SARS-CoV-2)	<u>Coronavirus disease 2019</u> (COVID-19)			<u>Yes</u>
<u>Coxsackie B virus</u>	<u>Coxsackie B virus</u> infection	Enterovirus infection is diagnosed mainly via <u>serological</u> tests such as <u>ELISA</u> and from cell culture.	There is no well-accepted treatment for the Coxsackie B group of viruses.	Under research ^[10]
<u>PRNP</u>	<u>Creutzfeldt–Jakob disease</u> (CJD)			No
<u>Crimean-Congo hemorrhagic fever virus</u>	<u>Crimean-Congo hemorrhagic fever</u> (CCHF)			No
<u>Cryptococcus neoformans</u>	<u>Cryptococcosis</u>	<u>India ink</u> of the <u>cerebrospinal fluid</u> (CSF)	<u>Intravenous Amphotericin B</u> combined with <u>flucytosine</u> by mouth	No
<u>Cryptosporidium</u> species	<u>Cryptosporidiosis</u>			No
usually <u>Ancylostoma braziliense</u> ; multiple other parasites	<u>Cutaneous larva migrans</u> (CLM)			No
<u>Cyclospora cayetanensis</u>	<u>Cyclosporiasis</u>			No
<u>Taenia solium</u>	<u>Cysticercosis</u>			No
<u>Cytomegalovirus</u>	<u>Cytomegalovirus</u> infection	Blood and urine tests, biopsy	<u>Cidofovir</u> , <u>foscarnet</u> , <u>ganciclovir</u> , <u>valganciclovir</u>	Under research ^[11]

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
Dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4) – <i>Flaviviruses</i>	<u>Dengue fever</u>	Clinical diagnosis	Treatment depends on the symptoms.	<u>Yes</u>
Green algae <i>Desmodemus armatus</i>	<u>Desmodemus infection</u>			No
<i>Dientamoeba fragilis</i>	<u>Dientamoebiasis</u>			No
<i>Corynebacterium diphtheriae</i>	<u>Diphtheria</u>	<p>Laboratory criteria</p> <ul style="list-style-type: none"> Isolation of <i>C. diphtheriae</i> culture Histopathologic diagnosis <p>Toxin demonstration</p> <ul style="list-style-type: none"> In vivo tests (guinea pig inoculation) In vitro test: Elek's gel precipitation test, PCR, ELISA, ICA <p>Clinical criteria</p> <ul style="list-style-type: none"> URT illness with sore throat Low-grade fever An adherent, dense, grey pseudomembrane covering the posterior aspect of the pharynx 	Metronidazole, Erythromycin, Procaine penicillin G	<u>Yes</u>
<i>Diphyllbothrium</i>	<u>Diphyllbothriasis</u>			No
<i>Dracunculus medinensis</i>	<u>Dracunculiasis</u>			No
Eastern equine encephalitis virus	Eastern equine encephalitis (EEE)	Blood tests	Corticosteroids, anticonvulsants, and supportive measures (treating symptoms)	Under research ^[12]
<u>Ebolavirus (EBOV)</u>	<u>Ebola hemorrhagic fever</u>			<u>Yes</u>
<i>Echinococcus</i> species	<u>Echinococcosis</u>	Imaging, Serology test	Surgical removal of the cysts combined with chemotherapy	No
<i>Ehrlichia</i> species	<u>Ehrlichiosis</u>			Under research ^[13]
<i>Enterobius vermicularis</i>	<u>Enterobiasis (Pinworm infection)</u>			No
<i>Enterococcus</i> species	<i>Enterococcus</i> infection			No
Enterovirus species	Enterovirus infection			No
<i>Rickettsia prowazekii</i>	<u>Epidemic typhus</u>			No
Parvovirus B19	<u>Erythema infectiosum (Fifth disease)</u>			No
Human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7)	<u>Exanthem subitum (Sixth disease)</u>			No
<i>Fasciola hepatica</i> and <i>Fasciola gigantica</i>	<u>Fasciolasis</u>			No
<i>Fasciolopsis buski</i>	<u>Fasciolopsiasis</u>			No
PRNP	<u>Fatal familial insomnia (FFI)</u>			No
Filarioidea superfamily	<u>Filariasis</u>			No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<i>Clostridium perfringens</i>	Food poisoning by <i>Clostridium perfringens</i>	Stool test	Supportive care	No
multiple	Free-living amebic infection			No
<i>Fusobacterium</i> species	<i>Fusobacterium</i> infection			No
usually <i>Clostridium perfringens</i> ; other <i>Clostridium</i> species	Gas gangrene (Clostridial myonecrosis)			No
<i>Geotrichum candidum</i>	Geotrichosis			No
PRNP	Gerstmann-Sträussler-Scheinker syndrome (GSS)			No
<i>Giardia lamblia</i>	Giardiasis	Detection of antigens on the surface of organisms in stool	Treatment is not always necessary. If medications are needed, a nitroimidazole medication is used such as metronidazole, tinidazole, secnidazole or ornidazole.	No
<i>Burkholderia mallei</i>	Glanders			No
<i>Gnathostoma spinigerum</i> and <i>Gnathostoma hispidum</i>	Gnathostomiasis			No
<i>Neisseria gonorrhoeae</i>	Gonorrhea	Gram stain and culture	Ceftriaxone by injection and azithromycin by mouth	Under research ^[14]
<i>Klebsiella granulomatis</i>	Granuloma inguinale (Donovanosis)			No
<i>Streptococcus pyogenes</i>	Group A streptococcal infection	Culture	Penicillin	No
<i>Streptococcus agalactiae</i>	Group B streptococcal infection	Gram stain	Penicillin and ampicillin	No
<i>Haemophilus influenzae</i>	<i>Haemophilus influenzae</i> infection	Gram stain	In severe cases, cefotaxime and ceftriaxone delivered into the bloodstream, and for the less severe cases, an association of ampicillin and sulbactam, cephalosporins of the second and third generation, or fluoroquinolones are preferred.	Yes
Enteroviruses, mainly Coxsackie A virus and enterovirus 71 (EV71)	Hand, foot and mouth disease (HFMD)	A diagnosis usually can be made by the presenting signs and symptoms alone. If the diagnosis is unclear, a throat swab or stool specimen may be taken.	Medications are usually not needed as hand, foot, and mouth disease is a viral disease that typically resolves on its own.	Under research ^{[15][16]}
Sin Nombre virus	Hantavirus Pulmonary Syndrome (HPS)			No
Heartland virus	Heartland virus disease			No
<i>Helicobacter pylori</i>	<i>Helicobacter pylori</i> infection			No
<i>Escherichia coli</i> O157:H7, O111 and O104:H4	Hemolytic-uremic syndrome (HUS)	First diagnosis of aHUS is often made in the context of an initial, complement-triggering infection, and Shiga-toxin has also been implicated as a trigger that identifies patients with aHUS.	Treatment involves supportive care and may include dialysis, steroids, blood transfusions, and plasmapheresis.	No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Bunyaviridae species</u>	<u>Hemorrhagic fever with renal syndrome (HFRS)</u>	HFRS is difficult to diagnose on clinical grounds alone and serological evidence is often needed.	There is no cure for HFRS. Treatment involves supportive therapy including renal dialysis.	No
<u>Hendra virus</u>	<u>Hendra virus infection</u>			No
<u>Hepatitis A virus</u>	<u>Hepatitis A</u>	Blood tests	Supportive care, <u>liver transplantation</u>	<u>Yes</u>
<u>Hepatitis B virus</u>	<u>Hepatitis B</u>	Blood tests	Antiviral medication (<u>tenofovir</u> , <u>interferon</u>), <u>liver transplantation</u>	<u>Yes</u>
<u>Hepatitis C virus</u>	<u>Hepatitis C</u>	Blood testing for <u>antibodies</u> or <u>viral RNA</u>	Antivirals (<u>sofosbuvir</u> , <u>simeprevir</u> , others)	<u>Under research</u> ^[17]
<u>Hepatitis D Virus</u>	<u>Hepatitis D</u>	Immunoglobulin G	Antivirals, pegylated interferon alpha	No
<u>Hepatitis E virus</u>	<u>Hepatitis E</u>	Hepatitis E virus (HEV)	Rest, <u>ribavirin</u> (if chronic)	<u>Yes</u>
<u>Herpes simplex virus 1 and 2 (HSV-1 and HSV-2)</u>	<u>Herpes simplex</u>	Based on symptoms, <u>PCR</u> , <u>viral culture</u>	<u>Aciclovir</u> , <u>valaciclovir</u> , <u>paracetamol</u> (acetaminophen), <u>topical lidocaine</u>	No
<u>Histoplasma capsulatum</u>	<u>Histoplasmosis</u>	Histoplasmosis can be diagnosed by samples containing the fungus taken from sputum (via bronchoalveolar lavage), blood, or infected organs.	In the majority of <u>immunocompetent</u> individuals, <u>histoplasmosis</u> resolves without any treatment. Typical treatment of severe disease first involves treatment with <u>amphotericin B</u> , followed by oral <u>itraconazole</u> .	No
<u>Ancylostoma duodenale and Necator americanus</u>	<u>Hookworm infection</u>			<u>Under research</u> ^[18]
<u>Human bocavirus (HBoV)</u>	<u>Human bocavirus infection</u>			No
<u>Ehrlichia ewingii</u>	<u>Human ewingii ehrlichiosis</u>	The diagnosis can be confirmed by using <u>PCR</u> . A peripheral blood smear can also be examined for intracytoplasmic inclusions called morulae.	<u>Doxycycline</u>	No
<u>Anaplasma phagocytophilum</u>	<u>Human granulocytic anaplasmosis (HGA)</u>	<u>PCR</u>	<u>Doxycycline</u>	No
<u>Human metapneumovirus (hMPV)</u>	<u>Human metapneumovirus infection</u>			No
<u>Ehrlichia chaffeensis</u>	<u>Human monocytic ehrlichiosis</u>	<u>PCR</u>	<u>Doxycycline</u>	No
<u>One of the human papillomaviruses</u>	<u>Human papillomavirus (HPV) infection</u>			<u>Yes</u>
<u>Human parainfluenza viruses (HPIV)</u>	<u>Human parainfluenza virus infection</u> <u>Croup</u>			<u>Under research</u> ^{[19][20]}
<u>Human T-lymphotropic virus 1 (HTLV-1)</u>	<u>Human T-lymphotropic virus 1 infection</u>			<u>Under research</u> ^{[21][22]}
<u>Hymenolepis nana and Hymenolepis diminuta</u>	<u>Hymenolepiasis</u>	Examination of the stool for eggs and parasites	<u>Praziquantel</u> , <u>niclosamide</u>	No
<u>Epstein–Barr virus (EBV)</u>	<u>Epstein–Barr virus infectious mononucleosis (Mono)</u>	Diagnostic modalities for infectious mononucleosis include: <ul style="list-style-type: none"> ▪ Person's age, with highest risk at 10 to 30 years. ▪ Medical history, such as close contact with 	Infectious mononucleosis is generally self-limiting, so only symptomatic or supportive treatments are used.	<u>Under research</u> ^[23]

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
		<p>other people with infectious mononucleosis</p> <ul style="list-style-type: none"> Physical examination, including palpation of any enlarged lymph nodes in the neck, or enlarged spleen. The heterophile antibody test is a screening test that gives results. Serological tests take longer time, but are more accurate. 		
<u>Orthomyxoviridae</u> species	<u>Influenza</u> (flu)	Diagnostic methods that can identify influenza include viral cultures, antibody- and antigen-detecting tests, and nucleic acid-based tests.	Treatment of influenza in cases of mild or moderate illness is supportive and includes anti-fever medications such as acetaminophen and ibuprofen, adequate fluid intake to avoid dehydration, and resting at home.	Under research ^[24]
				<u>Yes</u>
<u>Isospora belli</u>	<u>Isosporiasis</u>	Microscopic demonstration of the large typically shaped oocysts is the basis for diagnosis.	<u>Trimethoprim-sulfamethoxazole</u>	No
<u>Japanese encephalitis virus</u>	<u>Japanese encephalitis</u>	Available tests detecting JE virus-specific IgM antibodies in serum and/or cerebrospinal fluid, for example by IgM capture ELISA.	Supportive	<u>Yes</u>
unknown; evidence supports that it is infectious	<u>Kawasaki disease</u>	Based on symptoms, <u>ultrasound of the heart</u>	<u>Aspirin, immunoglobulin</u>	No
multiple	<u>Keratitis</u>		Infectious keratitis generally requires urgent antibacterial, antifungal, or antiviral therapy to eliminate the pathogen.	No
<u>Kingella kingae</u>	<u>Kingella kingae</u> infection			No
<u>PRNP</u>	<u>Kuru</u>	Autopsy	None	No
<u>Lassa virus</u>	<u>Lassa fever</u>	Laboratory testing	Supportive	No
<u>Legionella pneumophila</u>	Legionellosis (Legionnaires' disease)	Urinary <u>antigen test</u> , <u>sputum culture</u>	Effective <u>antibiotics</u> include most <u>macrolides</u> , <u>tetracyclines</u> , <u>ketolides</u> , and <u>quinolones</u> .	No
<u>Legionella pneumophila</u>	<u>Pontiac fever</u>			No
<u>Leishmania</u> species	<u>Leishmaniasis</u>	Hematology laboratory by direct visualization of the amastigotes (Leishman–Donovan bodies).	For visceral leishmaniasis in India, South America, and the Mediterranean, liposomal amphotericin B is the recommended treatment and is often used as a single dose.	Under research ^[25]
<u>Mycobacterium leprae</u> and <u>Mycobacterium lepromatosis</u>	<u>Leprosy</u>	<p>In countries where people are frequently infected, a person is considered to have leprosy if they have one of the following two signs:</p> <ul style="list-style-type: none"> Skin lesion consistent with leprosy and with definite sensory loss. 	<u>Rifampicin</u> , <u>dapsone</u> , <u>clofazimine</u>	Under research ^[26]

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
		<ul style="list-style-type: none"> Positive skin smears. 		
<i>Leptospira</i> species	Leptospirosis	Testing blood for antibodies against the bacterium or its DNA	Doxycycline, penicillin, ceftriaxone	Yes
<i>Listeria monocytogenes</i>	Listeriosis	Culture of blood or spinal fluid	Ampicillin, gentamicin	No
<i>Borrelia burgdorferi</i> , <i>Borrelia garinii</i> , and <i>Borrelia afzelii</i>	Lyme disease (Lyme borreliosis)	Based on symptoms, tick exposure, blood tests	Doxycycline, amoxicillin, ceftriaxone, cefuroxime	Under research ^[27]
<i>Wuchereria bancrofti</i> and <i>Brugia malayi</i>	Lymphatic filariasis (Elephantiasis)	Microscopic examination of blood	Albendazole with ivermectin or diethylcarbamazine	No
Lymphocytic choriomeningitis virus (LCMV)	Lymphocytic choriomeningitis	Blood test	Symptomatic and supportive	No
<i>Plasmodium</i> species	Malaria	Examination of the blood, antigen detection tests	Antimalarial medication	Yes
Marburg virus	Marburg hemorrhagic fever (MHF)	Blood test	Supportive	Under research ^[28]
Measles virus	Measles	Onset of fever and malaise about 10 days after exposure to the measles virus, followed by the emergence of cough, coryza, and conjunctivitis that worsen in severity over 4 days of appearing. Observation of Koplik's spots is also diagnostic.	Supportive care	Yes
Middle East respiratory syndrome-related coronavirus	Middle East respiratory syndrome (MERS)	rRT-PCR testing	Symptomatic and supportive	Under research ^[29]
<i>Burkholderia pseudomallei</i>	Melioidosis (Whitmore's disease)	Growing the bacteria in culture mediums	Ceftazidime, meropenem, co-trimoxazole	No
multiple	Meningitis	Lumbar puncture	Antibiotics, antivirals, steroids	No
<i>Neisseria meningitidis</i>	Meningococcal disease		Treatment in primary care usually involves intramuscular administration of benzylpenicillin. Once in the hospital, the antibiotics of choice are usually IV broad spectrum 3rd generation cephalosporins.	Yes
usually <i>Metagonimus yokagawai</i>	Metagonimiasis	Metagonimiasis is diagnosed by eggs seen in feces.	Praziquantel	No
Microsporidia phylum	Microsporidiosis	PCR	Fumagillin has been used in the treatment. Another agent used is albendazole.	No
Molluscum contagiosum virus (MCV)	Molluscum contagiosum (MC)	Based on appearance	Cimetidine, podophyllotoxin	No
Monkeypox virus	Mpox	Testing for viral DNA	Supportive, antivirals, vaccinia immune globulin	Yes
Mumps virus	Mumps	Antibody testing, viral cultures, and reverse transcription polymerase chain reaction	Supportive	Yes
<i>Rickettsia typhi</i>	Murine typhus (Endemic typhus)	Early diagnosis continued to be based on clinical suspicion.	The most effective antibiotics include tetracycline and chloramphenicol.	No
<i>Mycoplasma pneumoniae</i>	Mycoplasma pneumonia	Chest X-Ray, Chest CT, blood test	Erythromycin, doxycycline	No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<i>Mycoplasma genitalium</i>	<u>Mycoplasma genitalium infection</u>	Nucleic acid amplification test	<u>Azithromycin, moxifloxacin</u>	No
numerous species of bacteria (<u>Actinomycetoma</u>) and fungi (<u>Eumycetoma</u>)	<u>Mycetoma</u>	<u>Ultrasound, fine needle aspiration</u>	<u>Antibiotics or antifungal medication</u>	No
<u>parasitic dipterous fly larvae</u>	<u>Myiasis</u>	Examination and serologic testing	Petroleum jelly over the central punctum	No
most commonly <u>Chlamydia trachomatis</u> and <u>Neisseria gonorrhoeae</u>	<u>Neonatal conjunctivitis</u> (Ophthalmia neonatorum)		Antibiotic ointment (<u>erythromycin, tetracycline</u> , or rarely <u>silver nitrate</u> or <u>Argyrol</u>)	No
<u>Nipah virus</u>	<u>Nipah virus infection</u>			Under research ^[30]
<u>Norovirus</u>	<u>Norovirus</u>	Based on symptoms	<u>Supportive care</u>	Under research ^[31]
<u>PRNP</u>	(New) Variant Creutzfeldt–Jakob disease (vCJD, nvCJD)			No
usually <u>Nocardia asteroides</u> and other <u>Nocardia</u> species	<u>Nocardiosis</u>	chest x-ray to analyze the lungs, a bronchoscopy, a brain/lung/skin biopsy, or a sputum culture.	<u>trimethoprim/sulfamethoxazole</u> or high doses of <u>sulfonamides</u>	No
<u>Onchocerca volvulus</u>	<u>Onchocerciasis</u> (River blindness)			Under research ^[32]
<u>Opisthorchis viverrini</u> and <u>Opisthorchis felinus</u>	<u>Opisthorchiasis</u>			No
<u>Paracoccidioides brasiliensis</u>	<u>Paracoccidioidomycosis</u> (South American blastomycosis)			No
usually <u>Paragonimus westermani</u> and other <u>Paragonimus</u> species	<u>Paragonimiasis</u>			No
<u>Pasteurella</u> species	<u>Pasteurellosis</u>			No
<u>Pediculus humanus capitis</u>	<u>Pediculosis capitis</u> (Head lice)			No
<u>Pediculus humanus corporis</u>	<u>Pediculosis corporis</u> (Body lice)			No
<u>Pthirus pubis</u>	<u>Pediculosis pubis</u> (pubic lice, crab lice)			No
multiple	<u>Pelvic inflammatory disease</u> (PID)	Based on symptoms, <u>ultrasound, laparoscopic surgery</u>	Typical regimens include <u>cefoxitin</u> or <u>cefotetan</u> plus <u>doxycycline</u> , and <u>clindamycin</u> plus <u>gentamicin</u> .	No
<u>Bordetella pertussis</u>	<u>Pertussis</u> (whooping cough)	<u>Nasopharyngeal swab</u>	<u>erythromycin, clarithromycin</u> , or <u>azithromycin</u>	<u>Yes</u>
<u>Yersinia pestis</u>	<u>Plague</u>	Finding the bacterium in a lymph node, blood, sputum	<u>Gentamicin</u> and a <u>fluoroquinolone</u>	Under research ^[6]
<u>Streptococcus pneumoniae</u>	<u>Pneumococcal infection</u>	Culture	<u>cephalosporins</u> , and <u>fluoroquinolones</u> such as <u>levofloxacin</u> and <u>moxifloxacin</u>	<u>Yes</u>
<u>Pneumocystis jirovecii</u>	<u>Pneumocystis pneumonia</u> (PCP)	<u>chest X-ray</u> and an <u>arterial oxygen level</u>	<u>trimethoprim/sulfamethoxazole</u>	No
multiple	<u>Pneumonia</u>	Based on symptoms, <u>chest X-ray</u>	<u>Antibiotics, antivirals, oxygen therapy</u>	No
<u>Poliovirus</u>	<u>Poliomyelitis</u>	Finding the virus in the <u>feces</u> or <u>antibodies</u> in the	<u>supportive care</u>	<u>Yes</u>

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
		blood		
<i>Prevotella</i> species	<i>Prevotella</i> infection			No
usually <i>Naegleria fowleri</i>	Primary amoebic meningoencephalitis (PAM)	flagellation test	Miltefosine, fluconazole, amphotericin B, posaconazole, voriconazole, targeted temperature management	No
JC virus	Progressive multifocal leukoencephalopathy	finding JC virus DNA in spinal fluid, brain CT		No
<i>Chlamydophila psittaci</i>	Psittacosis	Culture	tetracyclines and chloramphenicol	No
<i>Coxiella burnetii</i>	Q fever	Based on serology	doxycycline, tetracycline, chloramphenicol, ciprofloxacin, and ofloxacin	Yes
Rabies virus	Rabies	fluorescent antibody test (FAT)	Supportive care	Yes
<i>Borrelia hermsii</i> , <i>Borrelia recurrentis</i> , and other <i>Borrelia</i> species	Relapsing fever	blood smear	Tetracycline-class antibiotics	No
Respiratory syncytial virus (RSV)	Respiratory syncytial virus infection	A variety of laboratory tests	Treatment for RSV infection is focused primarily on supportive care.	Under research ^[33]
<i>Rhinosporidium seeberi</i>	Rhinosporidiosis			No
Rhinovirus	Rhinovirus infection			No
<i>Rickettsia</i> species	Rickettsial infection			No
<i>Rickettsia akari</i>	Rickettsialpox			No
Rift Valley fever virus	Rift Valley fever (RVF)			No
<i>Rickettsia rickettsii</i>	Rocky Mountain spotted fever (RMSF)			No
Rotavirus	Rotavirus infection			Yes
Rubella virus	Rubella			Yes
<i>Salmonella</i> species	Salmonellosis			No
SARS coronavirus	Severe acute respiratory syndrome (SARS)			Under research ^[34]
<i>Sarcoptes scabiei</i>	Scabies			No
Group A <i>Streptococcus</i> species	Scarlet fever			No
<i>Schistosoma</i> species	Schistosomiasis			Under research ^[35]
multiple	Sepsis			No
<i>Shigella</i> species	Shigellosis (bacillary dysentery)			No
Varicella zoster virus (VZV)	Shingles (Herpes zoster)			Yes ^[36]
Variola major or Variola minor	Smallpox (variola)			Yes
<i>Sporothrix schenckii</i>	Sporotrichosis			No
<i>Staphylococcus</i> species	Staphylococcal food poisoning			No
<i>Staphylococcus</i> species	Staphylococcal infection			No
<i>Strongyloides stercoralis</i>	Strongyloidiasis			No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Measles virus</u>	<u>Subacute sclerosing panencephalitis</u>			<u>Yes</u>
<u>Treponema pallidum</u>	<u>Bejel, Syphilis, and Yaws</u>			Under research ^[37]
<u>Taenia species</u>	<u>Taeniasis</u>			No
<u>Clostridium tetani</u>	<u>Tetanus (lockjaw)</u>			<u>Yes</u>
<u>Tick-borne encephalitis virus (TBEV)</u>	<u>Tick-borne encephalitis</u>			<u>Yes</u>
usually <u>Trichophyton species</u>	<u>Tinea barbae (barber's itch)</u>			No
usually <u>Trichophyton tonsurans</u>	<u>Tinea capitis (ringworm of the scalp)</u>			No
usually <u>Trichophyton species</u>	<u>Tinea corporis (ringworm of the body)</u>			No
usually <u>Epidermophyton floccosum</u> , <u>Trichophyton rubrum</u> , and <u>Trichophyton mentagrophytes</u>	<u>Tinea cruris (Jock itch)</u>			No
<u>Trichophyton rubrum</u>	<u>Tinea manum (ringworm of the hand)</u>			No
usually <u>Hortaea werneckii</u>	<u>Tinea nigra</u>			No
usually <u>Trichophyton species</u>	<u>Tinea pedis (athlete's foot)</u>			No
usually <u>Trichophyton species</u>	<u>Tinea unguium (onychomycosis)</u>			No
<u>Malassezia species</u>	<u>Tinea versicolor (Pityriasis versicolor)</u>			No
<u>Staphylococcus aureus</u> or <u>Streptococcus pyogenes</u>	<u>Toxic shock syndrome (TSS)</u>			Under research ^{[38][39]}
<u>Toxocara canis</u> or <u>Toxocara cati</u>	<u>Toxocariasis (ocular larva migrans (OLM))</u>			No
<u>Toxocara canis</u> or <u>Toxocara cati</u>	<u>Toxocariasis (visceral larva migrans (VLM))</u>			No
<u>Toxoplasma gondii</u>	<u>Toxoplasmosis</u>			No
<u>Chlamydia trachomatis</u>	<u>Trachoma</u>			No
<u>Trichinella spiralis</u>	<u>Trichinosis</u>			No
<u>Trichomonas vaginalis</u>	<u>Trichomoniasis</u>			No
<u>Trichuris trichiura</u>	<u>Trichuriasis (whipworm infection)</u>			No
usually <u>Mycobacterium tuberculosis</u>	<u>Tuberculosis</u>			<u>Yes</u>
<u>Francisella tularensis</u>	<u>Tularemia</u>			Under research ^[40]
<u>Salmonella enterica subsp. enterica, serovar typhi</u>	<u>Typhoid fever</u>			<u>Yes</u>
<u>Rickettsia</u>	<u>Typhus fever</u>			No
<u>Ureaplasma urealyticum</u>	<u>Ureaplasma urealyticum infection</u>			No
<u>Coccidioides immitis</u> or <u>Coccidioides posadasii</u> . ^[41]	<u>Valley fever</u>			No

Infectious agent	Common name	Diagnosis	Treatment	Vaccine(s)
<u>Venezuelan equine encephalitis virus</u>	<u>Venezuelan equine encephalitis</u>			No
<u>Guanarito virus</u>	<u>Venezuelan hemorrhagic fever</u>			No
<u><i>Vibrio vulnificus</i></u>	<u><i>Vibrio vulnificus</i> infection</u>			No
<u><i>Vibrio parahaemolyticus</i></u>	<u><i>Vibrio parahaemolyticus</i> enteritis</u>			No
multiple viruses	<u>Viral pneumonia</u>			No
<u>West Nile virus</u>	<u>West Nile fever</u>			Under research ^[42]
<u><i>Trichosporon beigeli</i></u>	<u>White piedra (tinea blanca)</u>			No
<u><i>Yersinia pseudotuberculosis</i></u>	<u><i>Yersinia pseudotuberculosis</i> infection</u>			No
<u><i>Yersinia enterocolitica</i></u>	<u>Yersiniosis</u>			No
<u>Yellow fever virus</u>	<u>Yellow fever</u>			Yes
<u>Zeaspora fungus</u>	<u>Zeaspora</u>			No
<u><i>Zika virus</i></u>	<u>Zika fever</u>			Under research ^[43]
Mucorales order (Mucormycosis) and Entomophthorales order (Entomophthoramycosis)	<u>Zygomycosis</u>			No

See also

- Infections associated with diseases
- List of oncogenic bacteria
- List of causes of death by rate – including specific infectious diseases and classes thereof
- List of human disease case fatality rates
- List of vaccine topics

References

- Kuschner, R. A.; Russell, K. L.; Abuja, M.; Bauer, K. M.; Faix, D. J.; Hait, H.; Henrick, J.; Jacobs, M.; Liss, A.; Lynch, J. A.; Liu, Q.; Lyons, A. G.; Malik, M.; Moon, J. E.; Stubbs, J.; Sun, W.; Tang, D.; Towle, A. C.; Walsh, D. S.; Wilkerson, D.; Adenovirus Vaccine Efficacy Trial Consortium (2013). "A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. Military recruits". *Vaccine*. **31** (28): 2963–2971. doi:10.1016/j.vaccine.2013.04.035 (<https://doi.org/10.1016%2Fj.vaccine.2013.04.035>). PMID 23623865 (<https://pubmed.ncbi.nlm.nih.gov/23623865>).
- La Greca, F.; Magez, S. (2011). "Vaccination against trypanosomiasis: Can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323498>). *Human Vaccines*. **7** (11): 1225–1233. doi:10.4161/hv.7.11.18203 (<https://doi.org/10.4161%2Fhv.7.11.18203>). PMC 3323498 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323498>). PMID 22205439 (<https://pubmed.ncbi.nlm.nih.gov/22205439>).
- "Researchers a step closer to making HIV vaccine" (<http://www.medicalnewstoday.com/articles/258647.php>). *Medical News Today*. April 5, 2013. Retrieved April 24, 2013.
- Enria, Delia A.; Ambrosio, Ana M.; Briggiler, Ana M.; Feuillade, María R.; Crivelli, Eleonora; Grupo de Estudio de la Vacuna contra la Fiebre Hemorrágica Argentina (2010). "Vacuna contra la Fiebre Hemorrágica Argentina Candid#1 producida en la Argentina. Inmunogenicidad y seguridad" (https://www.medicinabuenosaires.com/demo/revistas/vol70-10/3/v70_n3_p215_222.pdf) [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety] (PDF). *Medicina* (in Spanish). **70** (3): 215–22. PMID 20529769 (<https://pubmed.ncbi.nlm.nih.gov/20529769>).

5. Negrón, María E.; Kharod, Grishma A.; Bower, William A.; Walke, Henry (22 February 2019). "Notes from the Field: Human *Brucella abortus* RB51 Infections Caused by Consumption of Unpasteurized Domestic Dairy Products — United States, 2017–2019" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385706>). *Morbidity and Mortality Weekly Report*. **68** (7): 185. doi:10.15585/mmwr.mm6807a6 (<https://doi.org/10.15585%2Fmmwr.mm6807a6>). PMC 6385706 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385706>). PMID 30789879 (<https://pubmed.ncbi.nlm.nih.gov/30789879>).
6. Titball, R. W.; Williamson, E. D. (2004). "Yersinia pestis (plague) vaccines". *Expert Opinion on Biological Therapy*. **4** (6): 965–973. doi:10.1517/14712598.4.6.965 (<https://doi.org/10.1517%2F14712598.4.6.965>). PMID 15174978 (<https://pubmed.ncbi.nlm.nih.gov/15174978>). S2CID 43565534 (<https://api.semanticscholar.org/CorpusID:43565534>).
7. Shivakumar, K. M.; Vidya, S. K.; Chandu, G. N. (2009). "Dental caries vaccine" (<https://doi.org/10.4103%2F0970-9290.49066>). *Indian Journal of Dental Research*. **20** (1): 99–106. doi:10.4103/0970-9290.49066 (<https://doi.org/10.4103%2F0970-9290.49066>). PMID 19336869 (<https://pubmed.ncbi.nlm.nih.gov/19336869>).
8. "Potential Chagas Vaccine Candidate Shows Unprecedented Efficacy" (<https://www.sciencedaily.com/releases/2013/03/130326194104.htm>). *Science Daily*. 26 March 2013. Retrieved 14 September 2013.
9. Docksai, Rick (31 May 2017). "DoD Vaccine Research Saves Military, Civilian Lives" (<http://www.defense.gov/Newsroom/News/Article/Article/1198160/dod-vaccine-research-saves-military-civilian-lives/>). US Department of Defense. Retrieved 7 July 2018.
10. Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines". *Expert Opinion on Biological Therapy*. **10** (2): 179–190. doi:10.1517/14712590903379502 (<https://doi.org/10.1517%2F14712590903379502>). PMID 20088713 (<https://pubmed.ncbi.nlm.nih.gov/20088713>). S2CID 2700243 (<https://api.semanticscholar.org/CorpusID:2700243>).
11. Schleiss, M. R. (2008). "Cytomegalovirus vaccine development". *Human Cytomegalovirus*. Current Topics in Microbiology and Immunology. Vol. 325. pp. 361–382. doi:10.1007/978-3-540-77349-8_20 (https://doi.org/10.1007%2F978-3-540-77349-8_20). ISBN 978-3-540-77348-1. PMC 2831992 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831992>). PMID 18637516 (<https://pubmed.ncbi.nlm.nih.gov/18637516>).
12. Pandya, J.; Gorchakov, R.; Wang, E.; Leal, G.; Weaver, S. C. (2012). "A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283035>). *Vaccine*. **30** (7): 1276–1282. doi:10.1016/j.vaccine.2011.12.121 (<https://doi.org/10.1016%2Fj.vaccine.2011.12.121>). PMC 3283035 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283035>). PMID 22222869 (<https://pubmed.ncbi.nlm.nih.gov/22222869>).
13. Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012). "Evaluation of an attenuated strain of *Ehrlichia canis* as a vaccine for canine monocytic ehrlichiosis". *Vaccine*. **31** (1): 226–233. doi:10.1016/j.vaccine.2012.10.003 (<https://doi.org/10.1016%2Fj.vaccine.2012.10.003>). PMID 23072894 (<https://pubmed.ncbi.nlm.nih.gov/23072894>).
14. "Collaboration to develop the world's first prophylactic gonorrhoea vaccine" (<https://web.archive.org/web/20200902235718/https://www.europeanpharmaceuticalreview.com/news/126412/collaboration-to-develop-the-worlds-first-prophylactic-gonorrhoea-vaccine/>). Archived from the original (<https://www.europeanpharmaceuticalreview.com/news/126412/collaboration-to-develop-the-worlds-first-prophylactic-gonorrhoea-vaccine/>) on 2020-09-02.
15. Zhu, F. C.; Liang, Z. L.; Li, X. L.; Ge, H. M.; Meng, F. Y.; Mao, Q. Y.; Zhang, Y. T.; Hu, Y. M.; Zhang, Z. Y.; Li, J. X.; Gao, F.; Chen, Q. H.; Zhu, Q. Y.; Chu, K.; Wu, X.; Yao, X.; Guo, H. J.; Chen, X. Q.; Liu, P.; Dong, Y. Y.; Li, F. X.; Shen, X. L.; Wang, J. Z. (2013). "Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial". *The Lancet*. **381** (9871): 1037–45. doi:10.1016/S0140-6736(12)61764-4 (<https://doi.org/10.1016%2FS0140-6736%2812%2961764-4>). PMID 23352749 (<https://pubmed.ncbi.nlm.nih.gov/23352749>). S2CID 27961719 (<https://api.semanticscholar.org/CorpusID:27961719>).
16. Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines". *Expert Opinion on Biological Therapy*. **10** (2): 179–190. doi:10.1517/14712590903379502 (<https://doi.org/10.1517%2F14712590903379502>). PMID 20088713 (<https://pubmed.ncbi.nlm.nih.gov/20088713>). S2CID 2700243 (<https://api.semanticscholar.org/CorpusID:2700243>).
17. "Hepatitis C vaccine by Inovio could be tested in humans by end of year" (<http://www.bizjournals.com/philadelphia/news/2013/01/09/hepatitis-c-vaccine-by-inovio-could-be.html>). *Philadelphia Business Journal*. January 9, 2013. Retrieved April 24, 2013.
18. "Human hookworm vaccine trial" (<http://www.medicalnewstoday.com/articles/240586.php>). *Medical News Today*. January 20, 2012. Retrieved April 24, 2013.

19. Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. (5 December 2001). "Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity" (<https://doi.org/10.1093/jnci%2F93.23.1775>). *Journal of the National Cancer Institute*. **93** (23): 1775–1783. doi:10.1093/jnci/93.23.1775 (<https://doi.org/10.1093%2Fjnci%2F93.23.1775>). PMID 11734593 (<https://pubmed.ncbi.nlm.nih.gov/11734593>).
20. De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (2007). "Human T Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine". *Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers*. Novartis Foundation Symposia. Vol. 187. pp. 47–60. doi:10.1002/9780470514672.ch4 (<https://doi.org/10.1002%2F9780470514672.ch4>). ISBN 978-0-470-51467-2. PMID 7796676 (<https://pubmed.ncbi.nlm.nih.gov/7796676>).
21. Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. (2001). "Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity" (<https://doi.org/10.1093/jnci%2F93.23.1775>). *Journal of the National Cancer Institute*. **93** (23): 1775–1783. doi:10.1093/jnci/93.23.1775 (<https://doi.org/10.1093%2Fjnci%2F93.23.1775>). PMID 11734593 (<https://pubmed.ncbi.nlm.nih.gov/11734593>).
22. De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (1994). "Human T Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine". *Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers*. Novartis Foundation Symposia. Vol. 187. pp. 47–55, discussion 55–60. doi:10.1002/9780470514672.ch4 (<https://doi.org/10.1002%2F9780470514672.ch4>). ISBN 9780470514672. PMID 7796676 (<https://pubmed.ncbi.nlm.nih.gov/7796676>). {{cite book}}: |journal= ignored (help)
23. Pullen, L.C. (November 7, 2011). "Epstein-Barr Virus Vaccine May Soon Enter Phase 3 Trial" (<http://www.medscape.com/viewarticle/753031>). *Medscape Today*. Retrieved April 24, 2013.
24. "H5N1 Influenza Virus Vaccine, manufactured by Sanofi Pasteur, Inc. Questions and Answers" (<https://www.fda.gov/vaccines-blood-biologics/vaccines/h5n1-influenza-virus-vaccine-manufactured-sanofi-pasteur-inc-questions-and-answers#:~:text=On%20April%2017%2C%202007%2C%20FDA,to%20the%20H5N1%20influenza%20virus>). FDA. 12 April 2019.
25. Nakkazi, E. (March 12, 2012). "New vaccine trials to prevent visceral leishmaniasis" (<https://web.archive.org/web/20130420144503/http://newsciencejournalism.com/03/2012/vaccine-trials-to-prevent-visceral-leishmaniasis-starts/>). *New Science Journalism*. Archived from the original on April 20, 2013. Retrieved June 16, 2013.
26. McGuinness, R. (November 20, 2012). "Search for leprosy vaccine continues as disease still affects thousands" (<http://metro.co.uk/2012/11/20/search-for-leprosy-vaccine-continues-as-disease-still-affects-thousands-620746/>). *Metro News*. Retrieved May 29, 2013.
27. "Lyme Disease Vaccine" (<http://www.lymeinfo.net/vaccine.html>). Lyme Info. Retrieved April 24, 2013.
28. Hampton, T. (2006). "Marburg Vaccine Shows Promise: Offers Postexposure Protection in Monkeys". *JAMA*. **295** (20): 2346. doi:10.1001/jama.295.20.2346 (<https://doi.org/10.1001%2Fjama.295.20.2346>). PMID 16720816 (<https://pubmed.ncbi.nlm.nih.gov/16720816>).
29. "MERS vaccine shows promise in clinical trial, say researchers" (<https://web.archive.org/web/20200503002825/https://www.europeanpharmaceuticalreview.com/news/117962/mers-vaccine-shows-promise-in-clinical-trial-say-researchers/>). Archived from the original (<https://www.europeanpharmaceuticalreview.com/news/117962/mers-vaccine-shows-promise-in-clinical-trial-say-researchers/>) on 2020-05-03.
30. "Developing a vaccine against Nipah virus" (<https://www.sciencedaily.com/releases/2019/04/190415081956.htm#:~:text=Summary%3A,viruses%20in%20the%20same%20family.&text=Nipah%20virus%20is%20a%20type,transmitted%20from%20animals%20to%20humans.>).
31. Sifferlin, A. (March 22, 2013). "Norovirus leading cause of intestinal disorders in kids" (<http://www.cnn.com/2013/03/22/health/norovirus-intestinal-disorders-time>). *CNN*. Retrieved April 24, 2013.
32. Sanjit Bagchi (April 26, 2006). "Study raises hopes of vaccine for river blindness" (<http://www.scidev.net/en/news/study-raises-hopes-of-vaccine-for-river-blindness.html>). *SciDev Net*. Retrieved April 24, 2013.
33. Lindell, D. M.; Morris, S. B.; White, M. P.; Kallal, L. E.; Lundy, P. K.; Hamouda, T.; Baker, J. R.; Lukacs, N. W. (2011). Semple, Malcolm Gracie (ed.). "A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137595>). *PLOS ONE*. **6** (7): e21823. Bibcode:2011PLoSO...621823L (<https://ui.adsabs.harvard.edu/abs/2011PLoSO...621823L>). doi:10.1371/journal.pone.0021823 (<https://doi.org/10.1371%2Fjournal.pone.0021823>). PMC 3137595 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137595>). PMID 21789184 (<https://pubmed.ncbi.nlm.nih.gov/21789184>).
34. Jiang, S.; Lu, L.; Du, L. (2013). "Development of SARS vaccines and therapeutics is still needed" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079997>). *Future Virology*. **8** (1): 1–2. doi:10.2217/fvl.12.126 (<https://doi.org/10.2217%2Ffvl.12.126>). PMC 7079997 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079997>). PMID 32201503 (<https://pubmed.ncbi.nlm.nih.gov/32201503>).
35. Siddiqui, A. A.; Siddiqui, B. A.; Ganley-Leal, L. (2011). "Schistosomiasis vaccines" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323497>). *Human Vaccines*. **7** (11): 1192–1197. doi:10.4161/hv.7.11.17017 (<https://doi.org/10.4161%2Fhv.7.11.17017>). PMC 3323497 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323497>). PMID 22048120 (<https://pubmed.ncbi.nlm.nih.gov/22048120>).

36. © This article incorporates text from this source, which is in the public domain: Lopez A, Harrington T, Marin M (2015). "Chapter 22: Varicella" (<https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html>). In Hamborsky J, Kroger A, Wolfe S (eds.). *Epidemiology and Prevention of Vaccine-Preventable Diseases* (<https://www.cdc.gov/vaccines/pubs/pinkbook/index.html>) (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
37. Cullen, P. A.; Cameron, C. E. (2006). "Progress towards an effective syphilis vaccine: The past, present and future". *Expert Review of Vaccines*. **5** (1): 67–80. doi:10.1586/14760584.5.1.67 (<https://doi.org/10.1586%2F14760584.5.1.67>). PMID 16451109 (<https://pubmed.ncbi.nlm.nih.gov/16451109>). S2CID 31534855 (<https://api.semanticscholar.org/CorpusID:31534855>).
38. Guilherme, L.; Ferreira, F. M.; Köhler, K. F.; Postol, E.; Kalil, J. (2013). "A Vaccine against *Streptococcus pyogenes*" (<https://doi.org/10.1007%2Fs40256-013-0005-8>). *American Journal of Cardiovascular Drugs*. **13** (1): 1–4. doi:10.1007/s40256-013-0005-8 (<https://doi.org/10.1007%2Fs40256-013-0005-8>). PMID 23355360 (<https://pubmed.ncbi.nlm.nih.gov/23355360>). S2CID 13071864 (<https://api.semanticscholar.org/CorpusID:13071864>).
39. Bagnoli, F.; Bertholet, S.; Grandi, G. (2012). "Inferring Reasons for the Failure of *Staphylococcus aureus* Vaccines in Clinical Trials" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417391>). *Frontiers in Cellular and Infection Microbiology*. **2**: 16. doi:10.3389/fcimb.2012.00016 (<https://doi.org/10.3389%2Ffcimb.2012.00016>). PMC 3417391 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417391>). PMID 22919608 (<https://pubmed.ncbi.nlm.nih.gov/22919608>).
40. Conlan, J. W. (2011). "Tularemia vaccines: Recent developments and remaining hurdles". *Future Microbiology*. **6** (4): 391–405. doi:10.2217/fmb.11.22 (<https://doi.org/10.2217%2Ffmb.11.22>). PMID 21526941 (<https://pubmed.ncbi.nlm.nih.gov/21526941>).
41. Walsh TJ, Dixon DM (1996). Baron S, et al. (eds.). *Spectrum of Mycoses*. In: *Baron's Medical Microbiology* (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1. (via NCBI Bookshelf) (<https://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.4006>).
42. Hall, R. A.; Khromykh, A. A. (2004). "West Nile virus vaccines". *Expert Opinion on Biological Therapy*. **4** (8): 1295–1305. doi:10.1517/14712598.4.8.1295 (<https://doi.org/10.1517%2F14712598.4.8.1295>). PMID 15268663 (<https://pubmed.ncbi.nlm.nih.gov/15268663>). S2CID 34176756 (<https://api.semanticscholar.org/CorpusID:34176756>).
43. Sifferlin, Alexandra (21 January 2016). "U.S. Launches 'Full-court Press' for a Zika Vaccine" (<https://time.com/4188973/zika-virus-vaccine-nih/>). *Time*. Retrieved 23 January 2016.
 - Chin J. B., ed. *Control of Communicable Diseases Manual*. 17th ed. APHA [American Public Health Association] Press; 2000. ISBN 978-0-87553-189-2
 - Red Book: 2009 Report of the Committee on Infectious Diseases. 2009. American Academy of Pediatrics. 28th ed. ISBN 978-1-58110-306-9
 - Centers for Disease Control and Prevention. *CDC Works 24/7* (<https://www.cdc.gov>). Retrieved on August 4, 2009.

Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_infectious_diseases&oldid=1284689551"